Ireland
--:--IST
Starting soon Observational

AI-based Progression and Medication Response Prediction Study in Parkinson's Disease

NCT07189468 · tracked via the Priya Life Science Spain tracker
Phase
Observational
Started
2025-10-06
Last updated
2025-09-24

Condition(s) studied

PARKINSON DISEASE (Disorder)

Investigational drug(s) / intervention(s)

Smartwatch and mobile application

Smartwatch and mobile application: Wearing a smartwatch and using a mobile application for one year

Study summary

The study aims to provide initial PoC validation data of two AI models to predict disease progression and treatment side effects in PD patients using as input patients' demographic, clinical and genetic information, as well as digital biomarker measurements in daily living collected via a smartwatch and a mobile application.

Eligibility

Sex
ALL
Min age
40 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Parkinson's disease diagnosis according to MDS criteria (Postuma et al., 2015) * Disease duration ranging from 5 to 10 years * Age 40-80 * Patients in stages 2 and 3 of the Hoehn and Yahr (a functional disability scale) in the ON condition * The participant is using a compatible smartphone * Written informed consent Exclusion Criteria: * Atypical Parkinsonian Syndrome * Second-line device-aided treatments * Patients with \>4 daily doses of L-DOPA * Daily levodopa equivalent dose \> 1500 mg * Ongoing hallucinations requiring short-term treatment adjustment * Inability to provide informed consent or participate in the study * Inability to use the smartwatch and/or the mAI-Care app - as judged by investigator * Lacking motivation to participate in study procedures - as judged by investigator * Under adult autonomy protection system, legal guardianship or incapacitation * Pregnant and breast-feeding women

Primary outcome measure(s)

  • Classification performance of the Parkinson's disease (PD) progression prediction model — Between baseline and 12 months
    Classification performance of the model in predicting observed motor disease progression, defined as a binary outcome: the condition of a patient is classified as worsened if either the Movement Disorder Society Unified Parkinson's Disease (MDS-UPDRS) rating scale part III score in ON-state increases by more than 3 points (\>3), or the Levodopa Equivalent Daily Dose (LEDD) increases by more than 10%.

Trial sites (4)

FacilityCityRegionStatus
University Hospital of Toulouse Toulouse France
Technische Universität Dresden Dresden Germany
Hospital Ruber Internacional Madrid Spain
Queen Mary University of London London United Kingdom

More University Hospital, Toulouse trials in Spain

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07189468 on ClinicalTrials.gov ↗ ← All trials in Spain